Key result
SMuRF-less NSTEMI is linked to ~45% lower 60-day MACE risk versus patients with standard risk factors.
Why the study?
Relatively little attention has been paid to the prevalence and prognosis of patients presenting with non-STEMI without standard modifiable risk factors (SMuRF-less).
Does SMuRF-less status improve short- and long-term MACE outcomes in patients presenting with NSTEMI compared to those with standard modifiable risk factors?
Cohort (n=8,196)
Yes
Does SMuRF-less status improve short- and long-term MACE outcomes in patients presenting with NSTEMI compared to those with standard modifiable risk factors?
SMuRF-less NSTEMI patients have significantly better short- and long-term cardiovascular outcomes compared to those with standard modifiable risk factors, contrasting with prior findings in STEMI populations.
May inform NSTEMI prognosis by SMuRF status; hypothesis-generating and contrasts with STEMI observations, needing prospective confirmation.
Patients with ST-elevation myocardial infarction (STEMI), but without standard modifiable risk factors (SMuRF-less), are surprisingly common and appear to have a worse, or at best similar, short-term prognosis. However, relatively little attention has been paid to the prevalence and prognosis of SMuRF-less patients with non-STEMI (NSTEMI). The aim of our study was to identify the proportion and outcomes of SMuRF-less NSTEMI patients in a large US healthcare population. Patients with NSTEMI between 2001–2021 presenting to Intermountain Healthcare hospitals and catheterization laboratories were included. SMuRF-less status was defined as no clinical diagnosis of, or treatment for, hypertension, hyperlipidemia, diabetes, and smoking. Outcomes were assessed at 60 days and long-term for major adverse cardiovascular events (MACE: death, myocardial infarction, and heart failure hospitalization). Multivariable Cox proportional hazard regression was used to determine MACE hazard ratios (HR) for SMuRF-less versus patients with SMuRF. NSTEMI patients totaled 8196, of which 1458 (17.8%) were SMuRF-less. SMuRF-less patients were younger, more frequently male, had fewer comorbidities, and were slightly less likely to have revascularization. For SMuRF-less patients, 60-day MACE outcomes were lower (adj HR = 0.55, p < 0.0001), and this persisted for long-term MACE outcomes (adj HR = 0.64, p < 0.0001) and for each of its components. In this large US healthcare population, SMuRF-less NSTEMI presentation, as with STEMI presentation, was found to be common (17.8%). However, unlike STEMI reports, short- and long-term outcomes were better for SMuRF-less patients. Further studies to increase understanding of risk factors and preventive measures for NSTEMI in SMuRF-less patients are indicated.
No takes yet. Share an insight, caveat, or question.
Anderson et al. (2023) conducted a cohort in Non-ST Elevation Myocardial Infarction (NSTEMI) (n=8,196). SMuRF-less status (absence of hypertension, hyperlipidemia, diabetes, and smoking) vs. Patients with standard modifiable risk factors (SMuRF) was evaluated on 60-day major adverse cardiovascular events (MACE: death, myocardial infarction, and heart failure hospitalization) (adj HR 0.55, p=< 0.0001). Presenting with NSTEMI without standard modifiable risk factors was associated with a lower risk of 60-day MACE compared to patients with these risk factors (adj HR 0.55, p < 0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: